Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bayer
Biotech
Bayer's blood thinner fails phase 3, denting $5B sales forecast
The factor XIa inhibitor had “inferior efficacy” to BMS and Pfizer’s Eliquis in a phase 3 trial, prompting Bayer to stop the study early.
Nick Paul Taylor
Nov 20, 2023 5:00am
Biopharma won’t stop betting big on M&A earnouts as payouts slow
Oct 17, 2023 6:00am
Bayer, Hologic join up on contrast-enhanced mammography scans
Sep 22, 2023 11:35am
Bayer preps phase 2 after Parkinson's cell therapy scores win
Aug 28, 2023 2:00am
Leaps by Bayer chief jumps to Bayer, too—Chutes & Ladders
Aug 25, 2023 9:30am
Bayer, AstraZeneca gain early access to Altis' 'digital twins'
Aug 24, 2023 8:00am
